Cancer burden in China: trends, risk factors and prevention

Sun, Dianqin; He, Li; Cao, Maomao; He, Siyi; Lei, Lin; Peng, Ji; Chen, Wanqing

doi:10.20892/j.issn.2095-3941.2020.0387

Cited by 150 publications

(131 citation statements)

References 120 publications

(56 reference statements)

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…As one of the most common malignant tumours worldwide, prostate cancer has a high morbidity and mortality, causing a major burden to society [ 1 , 27 , 28 ]. During the last few years, many studies have attempted to find a more effective treatment for CRPC and metastatic prostate cancer [ 29 – 31 ].…”

Section: Discussionmentioning

confidence: 99%

The cholesterol esterification inhibitor avasimibe suppresses tumour proliferation and metastasis via the E2F-1 signalling pathway in prostate cancer

et al. 2021

View full text Add to dashboard Cite

Background New effective drugs for prostate cancer (PCa) treatment are urgently needed. Avasimibe was recently identified as a promising drug for anticancer therapies. The main purpose of this study was to explore the effects and the underlying mechanisms of avasimibe in prostate cancer. Methods In this study, MTT and clonogenic survival assays were performed to detect cell proliferation after avasimibe treatment. The effect of avasimibe on cell migration was measured by wound healing and transwell migration assays. Cell cycle distribution and apoptosis were detected by flow cytometry. Immunofluorescence staining and western blot analysis were used to detect the expression of cell cycle-related proteins and epithelial-mesenchymal transition (EMT)-related proteins. In vivo, the antitumour effects of avasimibe were evaluated using a xenograft model and pulmonary metastasis model. Results The study found that avasimibe suppresses tumour growth and triggers G1 phase arrest. Moreover, the expression of the cell cycle-related proteins CDK2/4/6, Cyclin D1 and Cyclin A1 + A2 was significantly increased and p21 expression was decreased after avasimibe treatment. The migration of PCa cells was attenuated after treatment with avasimibe, followed by the downregulation of the expression of the EMT-related proteins N-cadherin, β-catenin, vimentin, Snail and MMP9 and upregulation of E-cadherin expression. Moreover, E2F-1 was elevated after treatment with avasimibe. After knockdown of E2F-1 expression, the inhibition of cell proliferation and migration caused by avasimibe was significantly recovered. The results of the xenograft model showed that avasimibe suppressed tumour growth in vivo. Immunofluorescence staining revealed lower levels of Ki67 and higher levels of E2F-1 in tumour tissues of the avasimibe group than those of the control group. A pulmonary metastasis model also confirmed the inhibition of PCa metastasis by avasimibe. The number of lung metastatic foci in the avasimibe group was significantly decreased compared with that in the control group. Conclusions Our results suggest that avasimibe can suppress tumour proliferation and metastasis via the E2F-1 signalling pathway. These findings demonstrate the potential of avasimibe as a new effective drug for PCa treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

The cholesterol esterification inhibitor avasimibe suppresses tumour proliferation and metastasis via the E2F-1 signalling pathway in prostate cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“…However, China now faces more challenging problems it shares with resource-rich countries including cardiovascular disease, chronic respiratory diseases, cancer, diabetes, and obesity. A recent series of publications 70 – 73 highlight achieving health equity should be China's foremost health goal. The current challenges include incomplete health insurance coverage, uneven health care access, mixed health care quality, escalating costs, and high risk of unsustainable expenditures on health care.…”

Section: Discussionmentioning

confidence: 99%

Toward the Cure of Acute Lymphoblastic Leukemia in Children in China

Chen

Zhang

Gale

et al. 2021

JCO Global Oncology

View full text Add to dashboard Cite

This study explored results of therapy of children with acute lymphoblastic leukemia (ALL) in China, recent progress, and challenges. Included are a survey of therapy outcomes of ALL in Chinese children nationwide, comparison of these data with global ALL therapy outcomes, analyses of obstacles to improving outcomes, and suggestions of how progress can be achieved. Therapy outcomes at many Chinese pediatric cancer centers are approaching those of resource-rich countries. However, nationwide outcomes still need improvement. Obstacles include suboptimal clinical trials participation, children without adequate health care funding, human resource shortages, especially physicians expert in pediatric hematology and oncology, and social-economic disparities. We suggest how these obstacles have been and continue to be remedied including expanded access to protocol-based therapy, improved supportive care, health care reforms, recruitment of trained personnel, and international collaborations. China has made substantial progress treating children with ALL. We envision even better outcomes in the near future.

show abstract

“…Lung cancer has becoming a great threat of global health due to its high incidence and mortality [ 62 ]. The five-year survival of this disease is relatively low, compared with other kinds of cancers [ 62 ]. A large proportion of patients were diagnosed when the lung cancer progressed to advanced stage.…”

Section: Discussionmentioning

confidence: 99%

Nitric oxide in occurrence, progress and therapy of lung Cancer: a systemic review and meta-analysis

Zhou

Li²,

Chen

et al. 2021

BMC Cancer

View full text Add to dashboard Cite

Background Nitric oxide (NO) plays an important role in lung cancer. However, the results of previous studies about NO in the occurrence, progress and therapy were not consistent. Therefore, we conducted a meta-analysis to evaluate the relationship between NO and lung cancer. Method We carried out comprehensive search in the databases, and collected related studies. The data of fraction of exhaled nitric oxide (FeNO) or blood NO in different populations (lung cancer patients and control subjects) and different time points (before therapy and after therapy) were extracted by two investigators. A random effect model was applied to analyze the differences of FeNO and blood NO in different populations and different time points. To further compare NO level of each subgroup with different pathological types and different stages, a network meta-analysis (NMA) was performed. Results Fifty studies including 2551 cases and 1691 controls were adopted in this meta-analysis. The FeNO (SMD 3.01, 95% CI 1.89–4.13, p < 0.00001) and blood NO (SMD 1.34, 95% CI 0.84–1.85, p < 0.00001) level in lung cancer patients was much higher than that in control subjects. NMA model indicated blood NO level in each cancer type except SCLC was higher than that in control patients. There was no significant difference of blood NO level among four kinds of lung cancer patients. Blood NO level in LCC patients (SUCRA = 83.5%) was the highest. Blood NO level in advanced stage but not early stage was higher than that in control subjects. Patients in advanced stage (SUCRA = 95.5%) had the highest blood NO level. No significant difference of FeNO (SMD -0.04, 95% CI -0.46-0.38, p > 0.05) and blood NO level (SMD -0.36, 95% CI -1.08-0.36, p > 0.05) was observed between pretreatment and posttreatment in all patients. However, FeNO level elevated (SMD 0.28, 95% CI 0.04–0.51, p = 0.02) and blood NO level decreased in NSCLC patients (SMD -0.95, 95% CI -1.89-0.00, p = 0.05) after therapy. Conclusion FeNO and blood NO level would contribute to diagnosis of lung cancer and evaluation of therapy effect, especially for NSCLC patients.

show abstract

Cancer burden in China: trends, risk factors and prevention

Cited by 150 publications

References 120 publications

The cholesterol esterification inhibitor avasimibe suppresses tumour proliferation and metastasis via the E2F-1 signalling pathway in prostate cancer

The cholesterol esterification inhibitor avasimibe suppresses tumour proliferation and metastasis via the E2F-1 signalling pathway in prostate cancer

Toward the Cure of Acute Lymphoblastic Leukemia in Children in China

Nitric oxide in occurrence, progress and therapy of lung Cancer: a systemic review and meta-analysis

Contact Info

Product

Resources

About